Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II registrational trial of ICP-022 in patients with relapsed/refractory mantle cell lymphoma

Next Previous
X
Search
Trial Profile

A Phase II registrational trial of ICP-022 in patients with relapsed/refractory mantle cell lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orelabrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors InnoCare Pharma

    • Most Recent Events

    • 28 Mar 2024 According to an InnoCare Pharma media release, the company expects to submit the NDA to the U.S. Food and Drug Administration (US FDA) in the third quarter of 2024.
    • 29 Aug 2023 According to an InnoCare Pharma media release, company expects to submit the NDA to the U.S. Food and Drug Administration (US FDA) in the middle of 2024.
    • 29 Aug 2023 Status changed from recruiting to active, no longer recruiting, according to an InnoCare Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top